Author

Peter D.R. Higgins 1

1 University of Michigan Health System School of Public Health

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan, Gareth Parkes, Pascal Juillerat, Krisztina Barbara Gecse, Xuan Yao, Wen Zhou, Huiwen Deng, Dapo Ilo, Yuri Sanchez Gonzalez, Peter D.R. Higgins

DEVELOPMENT OF THE ULCERATIVE COLITIS PATIENT-REPORTED OUTCOMES (UC-PRO) QUESTIONNAIRE

Gale Harding, Donald Patrick, Dennis Revicki, Sarah Trease, Gary Globe, Hema Viswanathan, Kristina Fitzgerald, Dominic Borie, Brian G. Ortmeier, Nancy Kline Leidy, Peter D.R. Higgins

DEVELOPMENT OF THE ULCERATIVE COLITIS PATIENT-REPORTED OUTCOMES (UC-PRO) QUESTIONNAIRE

Peter D.R. Higgins

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: combined results from 382 subjects in the phase 2b study U-ACHIEVE

Peter D.R. Higgins, Xavier Hebuterne, Jesse Siffledeen, Wen Zhou, Fabio Cataldi, Wangang Xie, Ana P. Lacerda, Silvio Danese

EFFICACY AND SAFETY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 2B STUDY U-ACHIEVE

William Sandborn, Subrata Ghosh, Julian Panés, Stefan Schreiber, Geert R. D'Haens, Satoshi Tanida, Jesse Siffledeen, Jose Enejosa, Wen Zhou, Ahmed A. Othman, Bidan Huang, Peter D.R. Higgins

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D.R. Higgins, Edward V. Loftus Jr., Severine Vermeire

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Severine Vermeire, Silvio Danese, Wen Zhou, Xuan Yao, Dapo Ilo, G Levy, Xavier Hebuterne, James O. Lindsay, Yuri Sanchez Gonzalez, Peter D.R. Higgins, Jean-Frédéric Colombel, Remo Panaccione

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease

Florian Rieder, Giovanni Latella, Fernando Jose Magro Dias, Elif Saritas Yuksel, Peter D.R. Higgins, Antonio Di Sabatino, Jessica R. de Bruyn, Jordi Rimola, J. Brito, Dominik Bettenworth, Gert Van Assche, Willem A. Bemelman, André D'Hoore, Gianluca Pellino, Axel Dignass

Item 1 - 10 / 18
1
2